Evidence map›Paper›PMID 37316633›Full record

ReviewRheumatology international2023

TNFα inhibitor biosimilar associated with polychondritis. A case-based review.

Aliki I Venetsanopoulou, Paraskevi V Voulgari, Alexandros A Drosos

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aliki I VenetsanopoulouDepartment of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece.ORCID http://orcid.org/0000-0003-4280-9193
Paraskevi V VoulgariDepartment of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece.ORCID http://orcid.org/0000-0002-5193-2284
Alexandros A DrososDepartment of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece. adrosos@uoi.gr.ORCID http://orcid.org/0000-0002-2232-0326
University of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsing polychondritis (RP) is a rare autoimmune disease characterized by inflammation of the cartilage structures of the body with typical features of auricular chondritis, nasal and ocular inflammation, audio-vestibular damage, as well as respiratory tract manifestations. It is associated with several autoimmune diseases and many other disorders. Tumor necrosis factor alpha (TNFα) inhibitors treat many chronic inflammatory disorders. They have proven effective and relatively safe in many clinical trials and observational studies. However, several autoimmune phenomena and paradoxical inflammation have been described with TNFα inhibitors, among them RP. This report presents a 43-year-old man with psoriatic arthritis treated with ABP-501 (Amgevita), an adalimumab (ADA) biosimilar and who developed RP, 8 months after the initiation of the treatment. This, is the first report of RP development during TNFα inhibitors biosimilar. We concluded that rheumatologists dealing with patients treated with TNFα inhibitors (originators or biosimilars), should be aware of several paradoxical reactions which may emerge and RP, is one of them.

Indexed as

Autoimmune DiseasesBiosimilar PharmaceuticalsPolychondritis, RelapsingAdultHumansImmunologic FactorsInflammationMaleTumor Necrosis Factor-alphaBiosimilar PharmaceuticalsImmunologic FactorsTumor Necrosis Factor-alphaABP-501Adalimumab biosimilarPsoriasisPsoriatic arthritisRelapsing polychondritisTNF inhibitors

Identifiers

PMID37316633
OpenAlexW4380589888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.